Giuliana Festi
Verona, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach.
Journal: The World Allergy Organization journal
Published: December 15, 2023
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response.
Journal: European journal of internal medicine
Published: September 16, 2021
Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?"
Journal: The journal of allergy and clinical immunology. In practice
Published: April 06, 2021
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase.
Journal: The journal of allergy and clinical immunology. In practice
Published: May 05, 2020
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Journal: Expert review of respiratory medicine
Published: October 09, 2019
Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life Perspective.
Journal: Journal of investigational allergology & clinical immunology
Published: January 25, 2019
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy.
Journal: The World Allergy Organization journal
Published: December 24, 2018
Fatal asthma; is it still an epidemic?
Journal: The World Allergy Organization journal
Published: June 26, 2016
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.
Journal: BMC pulmonary medicine
Published: November 23, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026